Real trading signals pulled from social media
Oscar Health is drawing fresh attention after two of its directors, David Plouffe and Jeffery H. Boyd, added shares on July 10. The insider buying wasn’t symbolic. It was coordinated. Both men acquired 14,134 shares each, according to Nasdaq filings. … Read more
Elevance Health (NYSE: ELV) is trading near $339, down from a 52-week high of $567. That’s a 40% slide in less than six months. The stock is under pressure from multiple angles. Medicaid cost inflation, sector-wide guidance withdrawals, and pending … Read more
Revenue growth like this doesn’t come from noise. It happens when a company locks in product fit and turns it into system-wide expansion. Two firms are now flashing numbers that match the kind of vertical control tech investors chase. Oscar … Read more
Lululemon is facing a pivotal moment in 2025. The brand, renowned for its premium activewear, is grappling with significant challenges that could reshape its trajectory in the coming months. Financial performance and outlook In Q2 2025, Lululemon reported a revenue … Read more
Oscar Health is not playing by the old insurance playbook. The company turned profitable in 2024 and is now projecting at least 20% compound annual revenue growth through 2027. That’s not a stretch goal. That’s internal guidance. EPS is expected … Read more
Oscar Health is being priced like an afterthought and performing like a breakout. The Q1 numbers confirm it, the insider trades back it, and the float is moving. This isn’t crowd hype. It’s internal conviction and raw financials that are … Read more
Oscar Health is not your grandfather’s insurance company. It is a digital-native operator that just posted $3.05 billion in Q1 revenue, up 42% year over year. Net income hit $275 million. That is not a typo. That is a profitable … Read more